Published in Cochrane Database Syst Rev on January 25, 2005
Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol (2008) 6.23
Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol (2010) 5.08
Meta-analysis of clear cell renal cell carcinoma gene expression defines a variant subgroup and identifies gender influences on tumor biology. Eur Urol (2011) 2.55
State of the science: an update on renal cell carcinoma. Mol Cancer Res (2012) 1.58
Targeted therapy in renal cell carcinoma. World J Urol (2008) 1.56
Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness. Br J Cancer (2009) 1.43
Metastatic renal cell cancer treatments: an indirect comparison meta-analysis. BMC Cancer (2009) 1.37
Treatment of metastatic renal cell carcinoma. Nat Rev Urol (2010) 1.24
C-reactive protein as a biomarker for urological cancers. Nat Rev Urol (2011) 1.21
A population-based study examining the effect of tyrosine kinase inhibitors on survival in metastatic renal cell carcinoma in Alberta and the role of nephrectomy prior to treatment. Can Urol Assoc J (2009) 1.17
Efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from the global randomized Phase 3 AXIS trial. Jpn J Clin Oncol (2013) 1.10
Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib. Mol Cancer (2011) 1.07
Antiangiogenic arming of an oncolytic vaccinia virus enhances antitumor efficacy in renal cell cancer models. J Virol (2009) 1.06
Lung cancer immunotherapy. Clin Med Res (2005) 1.04
Current status of targeted therapy for advanced renal cell carcinoma. Korean J Urol (2012) 1.02
Axitinib for the management of metastatic renal cell carcinoma. Drugs R D (2011) 1.01
Immunotherapeutic strategies in kidney cancer--when TKIs are not enough. Nat Rev Clin Oncol (2009) 1.01
Epigenetic regulation in RCC: opportunities for therapeutic intervention? Nat Rev Urol (2012) 0.99
Role of metastasectomy for metastatic renal cell carcinoma in the era of targeted therapy. World J Urol (2014) 0.99
Interleukin-2 in the treatment of unresectable or metastatic renal cell cancer: a systematic review and practice guideline. Can Urol Assoc J (2007) 0.99
Cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the United States: a SEER analysis. World J Urol (2012) 0.98
[Renal cell carcinoma 2008. Histopathology, molecular genetics and new therapeutic options]. Pathologe (2008) 0.98
Clinical uses of GM-CSF, a critical appraisal and update. Biologics (2008) 0.97
Inter and intratumour heterogeneity: a barrier to individualized medical therapy in renal cell carcinoma? Front Oncol (2012) 0.97
Treatment and overall survival in renal cell carcinoma: a Swedish population-based study (2000-2008). Br J Cancer (2013) 0.96
Targeting the Met signaling pathway in renal cancer. Expert Rev Anticancer Ther (2009) 0.96
A pilot study of monoclonal antibody cG250 and low dose subcutaneous IL-2 in patients with advanced renal cell carcinoma. Cancer Immun (2007) 0.96
AAV-mediated local delivery of interferon-beta for the treatment of retinoblastoma in preclinical models. Neuromolecular Med (2009) 0.95
Experience with sunitinib in the treatment of metastatic renal cell carcinoma. Ther Adv Urol (2012) 0.93
Spontaneous regression of metastatic renal cell carcinoma: case report. J Med Case Rep (2007) 0.93
Targeted therapy in renal cancer. Ther Adv Med Oncol (2009) 0.92
Algorithms in the First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma--Analysis Using Diagnostic Nodes. Oncologist (2015) 0.91
Common gamma chain cytokines in combinatorial immune strategies against cancer. Immunol Lett (2015) 0.91
Trends in the use of cytoreductive nephrectomy in the United States. Clin Genitourin Cancer (2012) 0.89
Interferon-γ-induced necrosis: an antitumor biotherapeutic perspective. J Interferon Cytokine Res (2013) 0.89
FDA drug approval summary: bevacizumab plus interferon for advanced renal cell carcinoma. Oncologist (2010) 0.89
Expression and prognostic significance of Src family members in renal clear cell carcinoma. Br J Cancer (2012) 0.86
Economic evaluation of first-line treatments for metastatic renal cell carcinoma: a cost-effectiveness analysis in a health resource-limited setting. PLoS One (2012) 0.86
Nuclear Receptor 4A1 (NR4A1) as a Drug Target for Renal Cell Adenocarcinoma. PLoS One (2015) 0.86
PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence. Onco Targets Ther (2014) 0.85
Systemic therapy for metastatic renal cell carcinoma: a review and update. Rev Urol (2012) 0.85
Retrospective Analysis of the Efficacy and Safety of Sorafenib in Chinese Patients With Metastatic Renal Cell Carcinoma and Prognostic Factors Related to Overall Survival. Medicine (Baltimore) (2015) 0.85
Adoptive cellular immunotherapy in metastatic renal cell carcinoma: a systematic review and meta-analysis. PLoS One (2013) 0.84
Anti-CD70 immunocytokines for exploitation of interferon-γ-induced RIP1-dependent necrosis in renal cell carcinoma. PLoS One (2013) 0.84
Targeted therapies in the management of renal cell carcinoma: role of bevacizumab. Biologics (2008) 0.84
Interferon-alfa in the treatment of patients with inoperable locally advanced or metastatic renal cell carcinoma: a systematic review. Can Urol Assoc J (2010) 0.84
Are all multi-targeted tyrosine kinase inhibitors created equal? An in vitro study of sunitinib and pazopanib in renal cell carcinoma cell lines. Can J Urol (2011) 0.83
Association between treatment effects on disease progression end points and overall survival in clinical studies of patients with metastatic renal cell carcinoma. Br J Cancer (2012) 0.83
Targeted therapy for metastatic renal cell carcinoma: current treatment and future directions. Ther Adv Med Oncol (2010) 0.81
The Significance of Metastasectomy in Patients with Metastatic Renal Cell Carcinoma in the Era of Targeted Therapy. Biomed Res Int (2015) 0.81
Immunotherapy in lung cancer. Transl Lung Cancer Res (2014) 0.80
Current status of cytokine therapy in management of patients with metastatic renal cell carcinoma. Can Urol Assoc J (2007) 0.80
Safety and efficacy of molecularly targeted agents in patients with metastatic kidney cancer with renal dysfunction. Anticancer Drugs (2011) 0.80
Antagonistic effects of chloroquine on autophagy occurrence potentiate the anticancer effects of everolimus on renal cancer cells. Cancer Biol Ther (2015) 0.80
New treatment options for metastatic renal cell carcinoma with prior anti-angiogenesis therapy. J Hematol Oncol (2017) 0.78
Tumour and patient factors in renal cell carcinoma-towards personalized therapy. Nat Rev Urol (2015) 0.78
Quantification of HLA class I molecules on renal cell carcinoma using Edman degradation. BMC Urol (2011) 0.78
Critical appraisal of pazopanib as treatment for patients with advanced metastatic renal cell carcinoma. Cancer Manag Res (2011) 0.78
Implications of Von Hippel-Lindau Syndrome and Renal Cell Carcinoma. J Kidney Cancer VHL (2015) 0.78
Cost-effectiveness of pazopanib compared with sunitinib in metastatic renal cell carcinoma in Canada. Curr Oncol (2016) 0.77
Renal cell carcinoma and the use of sorafenib. Ther Clin Risk Manag (2006) 0.77
Sunitinib treatment in patients with advanced renal cell cancer: the Brazilian National Cancer Institute (INCA) experience. Int Braz J Urol (2016) 0.77
Metastatic renal cell carcinoma: Current scenario and future trends. South Asian J Cancer (2012) 0.77
Anti-tumor effect of ribavirin in combination with interferon-α on renal cell carcinoma cell lines in vitro. Cancer Cell Int (2014) 0.77
Trial Watch: Therapeutic vaccines in metastatic renal cell carcinoma. Oncoimmunology (2015) 0.77
Sunitinib in the treatment of metastatic renal cell carcinoma. Ther Adv Urol (2016) 0.77
Time trend and age-period-cohort effect on kidney cancer mortality in Europe, 1981-2000. BMC Public Health (2006) 0.77
Induction of apoptosis by luteolin involving akt inactivation in human 786-o renal cell carcinoma cells. Evid Based Complement Alternat Med (2013) 0.77
Pharmacotherapy options in advanced renal cell carcinoma: what role for pazopanib? Clin Med Insights Oncol (2011) 0.77
Development of a novel interferon-α2b gene construct with a repetitive hypoxia-inducible factor binding site and its suppressive effects on human renal cell carcinoma cell lines in vitro. Int J Clin Oncol (2013) 0.77
Clinical experience and critical evaluation of the role of sorafenib in renal cell carcinoma. Open Access J Urol (2011) 0.77
Current status and perspective of antiangiogenic therapy for cancer: urinary cancer. Int J Clin Oncol (2006) 0.77
Defining risk status in the first-line treatment of metastatic renal cell carcinoma. J Cancer Res Clin Oncol (2010) 0.76
Interferon treatment for Japanese patients with favorable-risk metastatic renal cell carcinoma in the era of targeted therapy. Korean J Urol (2015) 0.76
Delivering preventive, predictive and personalised cancer medicine for renal cell carcinoma: the challenge of tumour heterogeneity. EPMA J (2011) 0.76
Nuclear expression of Lyn, a Src family kinase member, is associated with poor prognosis in renal cancer patients. BMC Cancer (2016) 0.75
Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma. Oncologist (2016) 0.75
Role of cytokine therapy for renal cell carcinoma in the era of targeted agents. Curr Oncol (2009) 0.75
Circulating biomarkers in renal cell carcinoma: the link between microRNAs and extracellular vesicles, where are we now? J Kidney Cancer VHL (2014) 0.75
Targeted Therapy for Metastatic Renal Carcinoma: an Update. J Kidney Cancer VHL (2014) 0.75
Management of metastatic renal cell carcinoma - mini review. J Kidney Cancer VHL (2015) 0.75
Heme oxygenase-1 is a predictive biomarker for therapeutic targeting of advanced clear cell renal cell carcinoma treated with sorafenib or sunitinib. Onco Targets Ther (2015) 0.75
State-of-the-art treatment of metastatic renal cell carcinoma. Curr Oncol (2009) 0.75
28-Year Survival following Several Metastasectomies, Going through 8th Line Systemic Therapy in a Case of mRCC. Case Rep Urol (2015) 0.75
Improving gene transfer in human renal carcinoma cells: Utilization of adenovirus vectors containing chimeric type 5 and type 35 fiber proteins. Exp Ther Med (2010) 0.75
[Immunotherapy for advanced renal cell cancer]. Urologe A (2015) 0.75
Comparative efficacy and safety of first-line treatments in patients with metastatic renal cell cancer: a network meta-analysis based on phase 3 RCTs. Oncotarget (2016) 0.75
Renal cell cancer: what can we learn from pre-operative studies? Front Oncol (2011) 0.75
Prolonged survival after sequential multimodal treatment in metastatic renal cell carcinoma: two case reports and a review of the literature. J Med Case Rep (2012) 0.75
miR-29b and miR-198 overexpression in CD8(+) T cells of renal cell carcinoma patients down-modulates JAK3 and MCL-1 leading to immune dysfunction. J Transl Med (2016) 0.75
How I treat renal cell carcinoma. J Oncol Pract (2008) 0.75
Treatment, Outcome and Prognostic Factors in Renal Cell Carcinoma - A Single Center Study (2000-2010). J Cancer (2016) 0.75
Cytoreductive Surgery in the Management of Renal Tumours: Rationale, Current Evidence and Future Perspectives. Indian J Surg Oncol (2016) 0.75
Individualising treatment choices in a crowded treatment algorithm. EJC Suppl (2013) 0.75
[Renal cell carcinoma]. Urologe A (2006) 0.75
Checkpoint inhibitors in the treatment of urological malignancies. ESMO Open (2017) 0.75
Moving beyond vascular endothelial growth factor-targeted therapy in renal cell cancer: latest evidence and therapeutic implications. Ther Adv Med Oncol (2017) 0.75
Progression-free survival of first-line treatment with molecular-targeted therapy may be a meaningful intermediate endpoint for overall survival in patients with metastatic renal cell carcinoma. Mol Clin Oncol (2017) 0.75
Cancer Immunotherapy, Part 2: Efficacy, Safety, and Other Clinical Considerations. P T (2017) 0.75
Patterns of initial management of node-negative breast cancer in two Canadian provinces. British Columbia/Ontario Working Group. CMAJ (1997) 3.74
Screening for prostate cancer. Cochrane Database Syst Rev (2006) 3.46
Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood (1999) 2.95
Localization of bronchial intraepithelial neoplastic lesions by fluorescence bronchoscopy. Chest (1998) 2.39
Emergency ultrasound-based algorithms for diagnosing blunt abdominal trauma. Cochrane Database Syst Rev (2005) 2.28
A three-year study of positive blood cultures, with emphasis on prognosis. Rev Infect Dis (1991) 2.13
Early versus deferred androgen suppression in the treatment of advanced prostatic cancer. Cochrane Database Syst Rev (2002) 2.07
DullRazor: a software approach to hair removal from images. Comput Biol Med (1997) 2.04
Soluble tumor necrosis factor receptors correlate with parasitemia and disease severity in human malaria. J Infect Dis (1992) 1.98
Quality of life in oncology practice: prognostic value of EORTC QLQ-C30 scores in patients with advanced malignancy. Eur J Cancer (1997) 1.85
Treatment decisions in palliative cancer care: patients' preferences for involvement and doctors' knowledge about it. Eur J Cancer (1997) 1.83
Sex-related differences in bronchial epithelial changes associated with tobacco smoking. J Natl Cancer Inst (1999) 1.64
A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma. Cancer Treat Rev (2008) 1.57
Systematic review and meta-analysis of antibiotic therapy for bone and joint infections. Lancet Infect Dis (2001) 1.53
Rapid translocation frequency analysis in humans decades after exposure to ionizing radiation. Int J Radiat Biol (1992) 1.43
[Evidence-based medicine and anaesthesiology--six steps towards implementation into clinical practice]. Anasthesiol Intensivmed Notfallmed Schmerzther (2003) 1.37
Targeted therapy for advanced renal cell carcinoma. Cochrane Database Syst Rev (2008) 1.35
A likelihood ratio approach to meta-analysis of diagnostic studies. J Med Screen (2003) 1.30
The association between population-based treatment guidelines and adjuvant therapy for node-negative breast cancer. British Columbia/Ontario Working Group. Br J Cancer (1997) 1.25
Chemical exposures, medical history, and risk of squamous and basal cell carcinoma of the skin. Cancer Epidemiol Biomarkers Prev (1996) 1.25
Systematic review and meta-analysis of emergency ultrasonography for blunt abdominal trauma. Br J Surg (2001) 1.20
[Emergency ultrasound for blunt abdominal trauma--meta-analysis update 2003]. Zentralbl Chir (2003) 1.15
Evaluation of immunohistochemical markers in non-small cell lung cancer by unsupervised hierarchical clustering analysis: a tissue microarray study of 284 cases and 18 markers. J Pathol (2004) 1.15
Tumor necrosis factor induces proliferation of neoplastic B cells from chronic lymphocytic leukemia. Blood (1989) 1.14
Bisphosphonates for advanced prostate cancer. Cochrane Database Syst Rev (2006) 1.08
Maximal androgen blockade for advanced prostate cancer. Cochrane Database Syst Rev (2000) 1.07
Practical aspects of quality-of-life measurement: design and feasibility study of the quality-of-life recorder and the standardized measurement of quality of life in an outpatient clinic. Cancer Treat Rev (1996) 1.05
A review of cochlear implantation in mitochondrial sensorineural hearing loss. Otol Neurotol (2003) 1.02
Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev (2000) 0.96
Abbreviated treatment for elderly, infirm, or noncompliant patients with limited-stage small-cell lung cancer. J Clin Oncol (1998) 0.95
Interventions for chronic abacterial prostatitis. Cochrane Database Syst Rev (2001) 0.95
Age of mothers with breast cancer and sex of their children. Br Med J (Clin Res Ed) (1981) 0.93
High levels of circulating soluble receptors for tumor necrosis factor in hairy cell leukemia and type B chronic lymphocytic leukemia. J Clin Invest (1992) 0.93
Human interleukin-7 induces proliferation of neoplastic cells from chronic lymphocytic leukemia and acute leukemias. Blood (1991) 0.92
Neoadjuvant (preoperative) chemotherapy for breast cancer. Cancer (1985) 0.91
Health effects of radiation incidents in the southern Urals. Stem Cells (1995) 0.90
Polymorphism within the second intron of the IL-1 receptor antagonist gene in patients with hematopoietic malignancies. Cytokines Mol Ther (1996) 0.90
Adjuvant hormone therapy for localised and locally advanced prostate carcinoma: a systematic review and meta-analysis of randomised trials. Cancer Treat Rev (2009) 0.89
Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer. Evid Rep Technol Assess (Summ) (1999) 0.88
[Reversible germ cell toxicity following aggressive chemotherapy in patients with testicular tumors: results of a prospective study]. Klin Wochenschr (1989) 0.88
Interleukin-6 stimulates the hypothalamus-pituitary-adrenocortical axis in man. J Clin Endocrinol Metab (1994) 0.87
Polymorphism of the tumour necrosis factor-alpha and lymphotoxin-alpha genes in chronic lymphocytic leukaemia. Br J Haematol (1997) 0.86
Epidemiology of high-grade prostatic intraepithelial neoplasia. Scand J Urol Nephrol Suppl (2000) 0.85
Stimulation of human NK-cell activity by cultured cells. I. Response of normals. Int J Cancer (1978) 0.85
Structural chromosome analysis by whole chromosome painting for assessment of radiation-induced genetic damage. J Radiat Res (1992) 0.85
Spontaneous interferon-alpha antibodies in a patient with pure red cell aplasia and recurrent cutaneous carcinomas. Ann Hematol (1991) 0.85
Surgery versus radiotherapy for muscle invasive bladder cancer. Cochrane Database Syst Rev (2002) 0.84
[Challenge of evidence-based medicine: sense and non-sense of diagnostic tests in gynecology]. Zentralbl Gynakol (2001) 0.84
Dose-response analyses among atomic bomb survivors exposed to low-level radiation. Health Phys (1987) 0.83
Evidence for the involvement of host-derived OKT8-positive T cells in the rejection of T-depleted, HLA-identical bone marrow grafts. Transplantation (1987) 0.83
Autocrine and paracrine regulation of neoplastic cell growth in hairy cell leukemia. Leuk Lymphoma (1995) 0.83
[Detection of tumorantigens of hypernephroma (author's transl)]. Urol Int (1973) 0.82
Comparison of German language versions of the QWB-SA and SF-36 evaluating outcomes for patients with prostate disease. Qual Life Res (2001) 0.81
[Methods of health economic evaluation for health services research]. Gesundheitswesen (2010) 0.81
Interferon-alpha antibodies in autoimmune diseases. J Interferon Res (1989) 0.81
Natural killer cell activity in preleukaemia. Lancet (1982) 0.81
p53 mutations in hairy cell leukemia. Leukemia (2000) 0.81
[Spontaneous remission of sudden deafness]. HNO (2000) 0.81
Impaired natural killer cell function in hemophiliacs with or without continuous substitution. Blut (1984) 0.80
Differential effect of GM-CSF and G-CSF in cyclic neutropenia. Lancet (1990) 0.80
The electrophoretic mobility test (EMT) and cancer diagnosis. Z Immunitatsforsch Immunobiol (1978) 0.80
Antibodies to interferon-alpha: a novel type of autoantibody occurring after allogeneic bone marrow transplantation. Bone Marrow Transplant (1996) 0.79
Tea tree oil: in vitro efficacy in otitis externa. J Laryngol Otol (2005) 0.78
[Lay assessment of health care services using therapy for rectal cancer as an example]. Zentralbl Chir (2008) 0.78
Physicians' decision-making in incompetent elderly patients: a comparative study between Austria, Germany (East, West), and Sweden. Int Psychogeriatr (1999) 0.78
Impaired T-cell and NK-cell function in patients with preleukemia. Blut (1982) 0.78
Frequency of reciprocal translocations and dicentrics induced in human blood lymphocytes by X-irradiation as determined by fluorescence in situ hybridization. Int J Radiat Biol (1993) 0.78
Tumor necrosis factor-alpha, but not lymphotoxin, stimulates growth of tumor cells in hairy cell leukemia. Leukemia (1990) 0.78
High-titre interferon-alpha antibodies in a patient with chronic graft-versus-host disease after allogeneic bone marrow transplantation. Bone Marrow Transplant (1994) 0.78
Bone densitometry and histomorphometry in patients with hairy cell leukemia. Leuk Lymphoma (1994) 0.78
Observations regarding hairy cell leukemia and chronic lymphocytic leukemia within the proposed new classification of lymphoid neoplasms. Blood (1995) 0.77
Polymorphism of the tumour necrosis factor-alpha and lymphotoxin-alpha genes in hairy cell leukaemia. Br J Haematol (1997) 0.77
Tumour necrosis factor and hairy cell leukaemia. Lancet (1988) 0.76
A phase I/II study of recombinant interferon alpha 2a and hydroxyurea for chronic myelocytic leukemia. Blut (1989) 0.76
Drug delivery analysis of the Canadian multicenter trial in non-small-cell lung cancer. J Clin Oncol (1994) 0.76
Preoperative adjuvant chemotherapy (neoadjuvant) for carcinoma of the breast: rationale and safety report. Recent Results Cancer Res (1985) 0.76
Receptors for tumor necrosis factor on neoplastic B cells from chronic lymphocytic leukemia are expressed in vitro but not in vivo. Blood (1990) 0.76
Neurophysiological effects of recombinant interferon-gamma and -alpha in man. Clin Physiol Biochem (1989) 0.75
Considerations on the pathogenesis of acute myeloid leukaemia in a splenectomized hairy cell leukaemia patient treated with interferon-alpha. Br J Haematol (1994) 0.75
The clinical evaluation of hairy cell leukemia. Blood (1992) 0.75
When should hairy cell leukaemia be treated? Lancet (1990) 0.75
Stimulation of human NK cell activity by cultured cells. II Ingestion of aspirin by blood donors suppresses induced NK activity. Clin Exp Immunol (1981) 0.75
[What is the benefit of mammography? -- mammography screening: careful consideration required]. Dtsch Med Wochenschr (2013) 0.75
[Comparative biochemical studies on transurethral and transvesical prostatectomy. II. Behavior of plasma hemoglobin and haptoglobin, protein and fat metabolism, phosphatases]. Bruns Beitr Klin Chir (1972) 0.75
[Alterations in serum proteins in patients with hypernephroma (author's transl)]. Urol Int (1974) 0.75
[Changes of blood coagulation in prostatic surgery, consequences for preventive therapy with antifibrinolytic agents]. Helv Chir Acta (1973) 0.75
[Proteinuria after physical exercise]. Dtsch Med Wochenschr (1972) 0.75
Meeting report: A Nomenclature for Classifying Aberrations Detected by Chromosome Painting. J Radiat Res (1993) 0.75
[Methods for determining proteins in urine]. Klin Wochenschr (1972) 0.75
Evidence for a paracrine pathway of B-cell stimulation in hairy cell leukaemia. Br J Haematol (1995) 0.75
Ratios of radiation-produced chromosome aberrations as indicators of large-scale DNA geometry during interphase. Radiat Res (1993) 0.75
[Panmyelopathy after administration of diclofenac?]. Dtsch Med Wochenschr (1979) 0.75
[Comparative biochemical studies on transurethral and transvesical prostatectomy. 3. Changes of blood coagulation following surgical intervention of the prostate]. Bruns Beitr Klin Chir (1973) 0.75
Human cytogenetic registers. A description of nine systems together with some recommendations. Cytogenet Cell Genet (1977) 0.75